newsfilter
← Latest News
Business Wire·

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

  • ImmunityBio senior leadership will present clinical & commercial priorities at the Jefferies Global Healthcare Conference & UBS Global Biopharma Conference in London during Life Sciences Week 2026 (Nov 15-20).
  • CEO Richard Adcock will discuss QUILT-2.005 study results regarding treating bladder cancer earlier in the disease course for patients not yet receiving BCG.
  • The UBS Global Biopharma Conference presentation is scheduled for Monday, Nov 16, from 10:40 to 11:10 GMT; registration is required via the provided webcast link.
  • The Jefferies Global Healthcare Conference fireside chat with Roger Song, MD, CFA, is scheduled for Monday, Nov 16, from 12:00 to 12:25 GMT; registration is required via the provided summitcast link.
  • ANKTIVA® (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor agonist indicated in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • The investigational use of ANKTIVA with BCG in BCG-naïve NMIBC patients is not yet FDA-approved; an sBLA submission timing remains uncertain per forward-looking statements.
  • Warnings include the risk of metastatic bladder cancer if cystectomy is delayed; clinicians should reconsider cystectomy if high-grade disease persists after two ANKTIVA/BCG induction courses.
  • Common adverse reactions (≥15%) include increased creatinine, dysuria, hematuria, urinary frequency, UTI, increased potassium, musculoskeletal pain, chills, & pyrexia.
  • ImmunityBio operates the Cancer BioShield™ platform, which combines the ANKTIVA fusion protein with adenovirus-vectored vaccines, allogeneic NK-cell therapies, & other immunomodulators.
  • The company faces risks related to regulatory approval timelines, commercialization success, supply chain disruptions, & potential changes in drug pricing policies in the US & EU.